Also known as: Biocytogen
Biocytogen is a biotechnology company focused on antibody-based drug R&D and preclinical research services. Its operations span gene editing services, animal models, antibody discovery, and innovative drug development with a base in China and international activities.
San Diego lab vacancy remains near record highs, with 31% of lab space sitting empty and asking rents falling for a 15th consecutive quarter to $5.55 per square foot. Leasing activity dropped to 223,000 square feet in the first quarter, while a handful of companies expanded or opened facilities in the market.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
